全球最新、最好的创新药物，什么时候能来中国？跨国药企赛诺菲正在用实际行动表明，中国可以是全球新药"第一站"。 2025年12月到2026年1月，短短数周内，赛诺菲连续有两款心血管药物在中国获批。它们分别是全球首发的新药阿夫凯泰片（商品名：星舒平 ），有着同类 最佳潜力，以及全球首创的普乐司兰钠注射液（商品名：瑞达普 ），填补了一处重要疾病领域的治疗空白。 实际上，赛诺菲的"心血管双子星"接连获批，也是与中国合作伙伴深度交融的结果，也是赛诺菲创新的BD（business development，业务拓展）模式的明 证。 2025年，堪称中国创新药BD交易爆发元年。医药魔方数据显示，中国创新药BD出海授权2025年交易总金额达到1356.55亿美元，再创历史新高。 在中国创新药纷纷借船出海时，赛诺菲中国则另辟蹊径。2022年底，总部授权赛诺菲中国引进管线的权力。此后，赛诺菲立足中国，主动深入中国本土创新 药生态，发掘最有潜力的药物分子，凭借自身雄厚的开发和商业化实力，让药物最早惠及中国患者。 2024年末以来，赛诺菲分别通过与箕星药业、维亚臻的BD合作，获得了阿夫凯泰片和普乐司兰钠注射液的大中华区开发及商业化权益 ...

Group 1: Market Overview - The U.S. stock market opened mixed on January 6, with the Dow Jones index down 0.09%, the S&P 500 index up 0.10%, and the Nasdaq Composite index up 0.30% [1] - Most popular Chinese concept stocks rose, with the Nasdaq China Golden Dragon Index up 0.35%, NIO, Xpeng Motors, and NetEase rising over 1%, while Alibaba fell over 1% [1] - Chip stocks saw a broad increase, with Microchip Technology rising 7.7% to its highest level since July, and NXP Semiconductors and TSMC rising over 2% [1] Group 2: Company News - Trump hinted to oil executives about significant changes in Venezuela's political situation a month before military actions, indicating oil's central role in U.S. decisions regarding Venezuela [2] - NVIDIA's CEO Jensen Huang stated that most cars will achieve autonomous or highly autonomous driving within the next decade, and the company released the Alpamayo series VLA open-source AI models for autonomous vehicle development [3] - Morgan Stanley filed with the SEC to launch ETFs linked to the prices of Bitcoin and Solana, aiming to enhance its influence in the cryptocurrency sector [4] - Sanofi announced the approval of its drug, Plerixafor injection (brand name: Rydapt), in China for lowering triglyceride levels in adult patients with familial chylomicronemia syndrome [5] - Bernstein lowered the target prices for several cryptocurrency stocks, including Coinbase from $510 to $440, Circle from $230 to $190, and Bullish from $60 to $50 [6]